Signant Health Acquires VirTrial
Signant Health has announced the acquisition of VirTrial, a provider of software solutions for remote site startup and decentralized clinical trial conduct.
In addition to VirTrial's tele-research platform, which includes secure video, audio, chat, and connected medical device capabilities for decentralized patient-site interaction and assessments, the agreement provides Signant with a solution to address remote site startup and monitoring. Known as Virtual Site Monitoring, the solution leverages wearable technology for in-house or outsourced clinical research associates to remotely conduct site evaluation, initiation, and monitoring visits.
For more information, click here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
